NextCure, Inc. (NXTC): Total Liabilities
$15.24M
As of 2025-12-31
$10.47M
As of 2026-06-30
-2.9%
3-year compound annual growth
+3.4%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $15.24M | -1.0% | 2026-03-05, Balance as of period end |
| 2024-12-31 | $15.39M | +13.0% | 2026-03-05, Balance as of period end |
| 2023-12-31 | $13.62M | -18.1% | 2025-03-06, Balance as of period end |
| 2022-12-31 | $16.63M | +84.8% | 2024-03-21, Balance as of period end |
| 2021-12-31 | $9.00M | -30.4% | 2023-03-02, Balance as of period end |
| 2020-12-31 | $12.92M | -62.7% | 2022-03-03, Balance as of period end |
| 2019-12-31 | $34.68M | +7.2% | 2021-03-04, Balance as of period end |
| 2018-12-31 | $32.35M | n/a | 2020-03-12, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| NextCure, Inc. (NXTC) | 2025-12-31 | $15.24M | -1.0% |
| Opus Genetics, Inc. (IRD) | 2025-12-31 | $34.90M | +208.9% |
| Coya Therapeutics, Inc. (COYA) | 2025-12-31 | $6.92M | +45.1% |
| Unicycive Therapeutics, Inc. (UNCY) | 2025-12-31 | $18.94M | -21.9% |
| Hyperion Defi, Inc. (HYPD) | 2025-12-31 | $10.70M | -36.1% |
| Actinium Pharmaceuticals, Inc. (ATNM) | 2025-12-31 | $43.94M | -0.5% |
| Vistagen Therapeutics, Inc. (VTGN) | 2026-03-31 | $13.04M | -6.5% |
| Akari Therapeutics Plc (AKTX) | 2025-12-31 | $19.56M | -30.9% |
| Atossa Therapeutics, Inc. (ATOS) | 2025-12-31 | $8.26M | +66.2% |
Compare NXTC, IRD, COYA, UNCY side by side · Screen every company in Pharmaceutical Preparations ↗